Back to today’s briefing

Story perspectives

MIT Study Warns: 40% NIH Funding Cut Threatens Drug Approvals

9/27/2025

46 8 Full Breakdown

Summary

Story summary

MIT researchers assess the impact of a proposed 40% NIH funding cut on drug approvals since 2000.
The study finds over 50% of Food and Drug Administration (FDA)-approved small-molecule drugs cite NIH research, 7.1% directly linked to NIH funding.
Gleevec is cited as an NIH-supported cancer-drug example.
Researchers caution the study may underestimate NIH contributions and warn of long-term harm.

1 of 1

Story summary

MIT researchers assess the impact of a proposed 40% NIH funding cut on drug approvals since 2000.
The study finds over 50% of Food and Drug Administration (FDA)-approved small-molecule drugs cite NIH research, 7.1% directly linked to NIH funding.
Gleevec is cited as an NIH-supported cancer-drug example.
Researchers caution the study may underestimate NIH contributions and warn of long-term harm.